壽康集團(00575.HK)中期由盈轉虧至2006.2萬美元
格隆匯8月30日丨壽康集團(00575.HK)公佈2022年中期業績,期內集團實現收益8.8萬美元,同比下降97.6%;公司股東應占虧損2006.2萬美元,上年同期為盈利266.1萬美元;每股基本虧損0.836美仙。
公吿稱,期內虧損主要由於:(i)無形資產的攤銷費用約1234萬美元(屬非現金項目);(ii)公司股本投資組合內的透過損益賬按公允價值處理的金融資產的已變現及未變現按市值計價虧損分別約100萬美元及336萬美元;(iii)集團的營運及研發開支約301萬美元;及(iv)公司衍生金融工具的未變現虧損約為69萬美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.